Maryland House Bill HB1380

Maryland 2026 Regular Session

• Introduced: 2/13/26
• Refer: 2/13/26

Caption

Health Insurance - Prescriptions for Gender-Affirming Care and Hormone Therapy - Coverage and Dispensing Requirements

Impact

The enactment of HB 1380 is expected to significantly modify healthcare practices regarding hormone-related treatments in Maryland. By requiring that health insurance entities cover gender-affirming prescriptions, the bill aims to remove barriers that patients may face in accessing necessary treatments, ultimately fostering better health outcomes. It also introduces specific guidelines that pharmacists must follow when dispensing medications, which is anticipated to streamline processes in pharmacies and improve patient adherence to treatment plans.

Summary

House Bill 1380 addresses health insurance coverage for prescriptions related to gender-affirming care and hormone therapy. The bill mandates that insurers, non-profit health service plans, and health maintenance organizations provide coverage for a supply of qualifying prescriptions under specific conditions. It establishes dispensing requirements, allowing pharmacists to dispense up to a 12-month supply of medications related to these treatments, enhancing access for individuals in need of continued care.

Contention

There may be points of contention surrounding HB 1380, particularly regarding its implications for insurers and healthcare providers. Some stakeholders may argue that it adds financial burdens to insurance companies, potentially increasing premiums. Furthermore, there could be debates over the terminology and definitions used in the bill concerning what constitutes gender-affirming treatment and the criteria for qualifying prescriptions. The broader societal discussions related to gender identity may also influence the level of support for the bill within the legislative process.